Back to List View Graph View

Glial fibrillary acidic protein

Glial fibrillary acidic protein (GFAP) is a structural protein primarily expressed in astrocytes and other glial cells within the central nervous system.

Where the papers sit

21 papers from the last 6 months study glial fibrillary acidic protein directly · updated from PubMed 10 Nov 2026

Study type 0 clinical trials · 14 observational · 6 human data · 1 preclinical

Themes 4 themes

  • Blood Biomarkers of Neurological Disease

    NfL and GFAP are being positioned as complementary blood markers for diagnosis, prognosis and monitoring across neurological disease. NfL more often tracks axonal injury and prognosis, while GFAP reflects astroglial damage and disease activity. Applications span hepatic encephalopathy, autoimmune encephalitis, epilepsy, myasthenia gravis, multiple sclerosis and transient ischemic attack. Cohorts remain heterogeneous, leaving disease-specific thresholds and clinical utility unresolved.

    9 papers · 42.9%

  • Emergency TBI Biomarker Testing

    GFAP combined with UCH-L1 is moving from diagnostic validation toward routine emergency-department use in mild traumatic brain injury. Studies assess whether the blood test can guide CT decisions and improve patient management. Real-world implementation remains constrained by preanalytical issues, especially hemolysis affecting UCH-L1 measurements. Protocols are extending evaluation into broader clinical and perinatal settings.

    5 papers · 23.8%

  • Alzheimer’s Disease Progression

    Blood proteomic markers are being linked to Alzheimer’s disease biology and long-term cognitive decline across the lifespan. Longitudinal work in Down syndrome and midlife and late-life cohorts seeks predictors of memory loss and progression. GFAP and NfL recur as indicators of neurodegeneration alongside broader protein signatures. Mechanistic studies additionally examine TLR4/RAGE and NF-kB signaling, but translation from biomarker association to effective intervention remains open.

    4 papers · 19%

  • Blood GFAP in Brain Injury

    Serum GFAP is moving toward rapid, minimally invasive discrimination of ischemic stroke and traumatic brain injury. Prospective stroke cohorts are defining its temporal profile and clinical value alongside imaging. Ultrasensitive ELISA and nanophotonic multiplex assays aim to improve detection across blood, urine and saliva. The key open question is whether assay gains translate into reliable early triage.

    3 papers · 14.3%

Glial Fibrillary Acidic Protein (GFAP)

Papers

The 21 papers from the last 6 months that study glial fibrillary acidic protein directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Blood Biomarkers of Neurological Disease (9)
  1. Blood biomarkers of brain damage in Transient Ischemic Attack: the role of plasma NfL and GFAP. Journal of neurology · 9 Sept 2026 PMID 42711449
  2. Exploring serum biomarkers in paediatric psychiatry: the impact of NfL and GFAP. Translational psychiatry · 26 Aug 2026 PMID 42649149
  3. Kappa Free Light Chain for Diagnosis and Neurofilament Light Chain for Prognosis in Autoimmune Encephalitis. Neurology(R) neuroimmunology & neuroinflammation · 3 Aug 2026 PMID 42546229
  4. Neurofilament Light Chain in Cerebrospinal Fluid and Blood Identifies Patients With Minimal and Overt Hepatic Encephalopathy. Liver international : official journal of the International Association for the Study of the Liver · 9 Jul 2026 PMID 42422896
  5. Application of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) as biomarkers in the clinical management of multiple sclerosis (NeuroFilMS): a protocol for an observational cohort study. BMJ open · 8 Jul 2026 PMID 42419882
  6. Evaluation of plasma neurofilament light chain and glial fibrillary acidic protein in myasthenia gravis: A controlled cohort study. PloS one · 7 Jul 2026 PMID 42412876
  7. Serum biomarkers remain stable after transitioning from intravenous to subcutaneous natalizumab in multiple sclerosis. Journal of neurology · 22 Jun 2026 PMID 42332277
  8. Plasma central nervous system biomarkers in heavily treatment-experienced people with HIV in the PRESTIGIO registry. AIDS (London, England) · 28 May 2026 PMID 42207142
  9. Differences in Neurofilament Light Chain, Glial Fibrillary Acidic Protein, and Tau Protein Levels in Patients with Temporal Lobe Epilepsy and Comorbid Depression. Molecular neurobiology · 26 May 2026 PMID 42189430
Emergency TBI Biomarker Testing (5)
  1. Impact of routine use of the GFAP and UCH-L1 TBI blood test for management of mild TBI on patient care in a European emergency department. European journal of trauma and emergency surgery : official publication of the European Trauma Society · 14 Aug 2026 PMID 42599452
  2. Umbilical cord blood biomarkers of neuronal injury in sleep-disordered breathing during pregnancy. Scientific reports · 19 Jul 2026 PMID 42472855
  3. Blood-based biomarkers GFAP/UCH-L1 for the diagnosis of mild traumatic brain injury (mTBI): a single-center implementation experience. European journal of trauma and emergency surgery : official publication of the European Trauma Society · 24 Jun 2026 PMID 42340459
  4. Capillary UCH-L1 protein blood measurement is affected by sample hemolysis. Clinical chemistry and laboratory medicine · 19 Jun 2026 PMID 42316320
  5. Study protocol for investigating real-world implementation of a combined glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) blood test in the management of adult mild traumatic brain injury in a single-centre European emergency department: the IMPACTS-BRAINI study. BMJ open · 18 Jun 2026 PMID 42315262
Alzheimer’s Disease Progression (4)
  1. Midlife and Late-Life Alzheimer Disease Blood Biomarkers and 11-Year Cognitive Decline. Neurology · 16 Oct 2026 PMID 42886876
  2. Neuroprotective Effect of Isorhapontigenin (ISO) Against LPS-Induced Neurodegenerative Condition via TLR4/RAGE-Mediated p-NF-kB Activation. Molecular neurobiology · 5 Sept 2026 PMID 42700283
  3. Longitudinal Dynamics of the Blood Proteome Within the Alzheimer Spectrum in Down Syndrome. Neurology · 1 Sept 2026 PMID 42679336
  4. Postoperative changes in circulating brain injury biomarkers in relation to long-term fatigue and cognitive outcomes after surgery for nonfunctioning pituitary adenomas. Pituitary · 1 Jul 2026 PMID 42384349
Blood GFAP in Brain Injury (3)
  1. Click-Chemistry-Enhanced Dynamic Light Scattering Immunoassay for Ultrasensitive GFAP Detection in Traumatic Brain Injury. Analytical chemistry · 18 Aug 2026 PMID 42610888
  2. Temporal Pattern and Clinical Value of Serum GFAP in Acute Ischemic Stroke: Results from Two Prospective German Cohorts. Translational stroke research · 15 Jun 2026 PMID 42295622
  3. AI-Enhanced Nanophotonic Heterochain Sensor Enables Multiplexed Biomarker Detection across Serum, Urine, and Saliva for Stroke Differentiation. ACS applied bio materials · 21 May 2026 PMID 42166366

By study type

Observational studies and case reports (14)
  1. Midlife and Late-Life Alzheimer Disease Blood Biomarkers and 11-Year Cognitive Decline. Neurology · 16 Oct 2026 PMID 42886876
  2. Blood biomarkers of brain damage in Transient Ischemic Attack: the role of plasma NfL and GFAP. Journal of neurology · 9 Sept 2026 PMID 42711449
  3. Longitudinal Dynamics of the Blood Proteome Within the Alzheimer Spectrum in Down Syndrome. Neurology · 1 Sept 2026 PMID 42679336
  4. Impact of routine use of the GFAP and UCH-L1 TBI blood test for management of mild TBI on patient care in a European emergency department. European journal of trauma and emergency surgery : official publication of the European Trauma Society · 14 Aug 2026 PMID 42599452
  5. Kappa Free Light Chain for Diagnosis and Neurofilament Light Chain for Prognosis in Autoimmune Encephalitis. Neurology(R) neuroimmunology & neuroinflammation · 3 Aug 2026 PMID 42546229
  6. Neurofilament Light Chain in Cerebrospinal Fluid and Blood Identifies Patients With Minimal and Overt Hepatic Encephalopathy. Liver international : official journal of the International Association for the Study of the Liver · 9 Jul 2026 PMID 42422896
  7. Application of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) as biomarkers in the clinical management of multiple sclerosis (NeuroFilMS): a protocol for an observational cohort study. BMJ open · 8 Jul 2026 PMID 42419882
  8. Evaluation of plasma neurofilament light chain and glial fibrillary acidic protein in myasthenia gravis: A controlled cohort study. PloS one · 7 Jul 2026 PMID 42412876
  9. Postoperative changes in circulating brain injury biomarkers in relation to long-term fatigue and cognitive outcomes after surgery for nonfunctioning pituitary adenomas. Pituitary · 1 Jul 2026 PMID 42384349
  10. Blood-based biomarkers GFAP/UCH-L1 for the diagnosis of mild traumatic brain injury (mTBI): a single-center implementation experience. European journal of trauma and emergency surgery : official publication of the European Trauma Society · 24 Jun 2026 PMID 42340459
  11. Serum biomarkers remain stable after transitioning from intravenous to subcutaneous natalizumab in multiple sclerosis. Journal of neurology · 22 Jun 2026 PMID 42332277
  12. Study protocol for investigating real-world implementation of a combined glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) blood test in the management of adult mild traumatic brain injury in a single-centre European emergency department: the IMPACTS-BRAINI study. BMJ open · 18 Jun 2026 PMID 42315262
  13. Temporal Pattern and Clinical Value of Serum GFAP in Acute Ischemic Stroke: Results from Two Prospective German Cohorts. Translational stroke research · 15 Jun 2026 PMID 42295622
  14. Plasma central nervous system biomarkers in heavily treatment-experienced people with HIV in the PRESTIGIO registry. AIDS (London, England) · 28 May 2026 PMID 42207142
Human data, design not indexed (6)
  1. Exploring serum biomarkers in paediatric psychiatry: the impact of NfL and GFAP. Translational psychiatry · 26 Aug 2026 PMID 42649149
  2. Click-Chemistry-Enhanced Dynamic Light Scattering Immunoassay for Ultrasensitive GFAP Detection in Traumatic Brain Injury. Analytical chemistry · 18 Aug 2026 PMID 42610888
  3. Umbilical cord blood biomarkers of neuronal injury in sleep-disordered breathing during pregnancy. Scientific reports · 19 Jul 2026 PMID 42472855
  4. Capillary UCH-L1 protein blood measurement is affected by sample hemolysis. Clinical chemistry and laboratory medicine · 19 Jun 2026 PMID 42316320
  5. Differences in Neurofilament Light Chain, Glial Fibrillary Acidic Protein, and Tau Protein Levels in Patients with Temporal Lobe Epilepsy and Comorbid Depression. Molecular neurobiology · 26 May 2026 PMID 42189430
  6. AI-Enhanced Nanophotonic Heterochain Sensor Enables Multiplexed Biomarker Detection across Serum, Urine, and Saliva for Stroke Differentiation. ACS applied bio materials · 21 May 2026 PMID 42166366
Preclinical: animal, cell and lab studies (1)
  1. Neuroprotective Effect of Isorhapontigenin (ISO) Against LPS-Induced Neurodegenerative Condition via TLR4/RAGE-Mediated p-NF-kB Activation. Molecular neurobiology · 5 Sept 2026 PMID 42700283